Nanobac Pharmaceuticals Valuation
| NNBP Stock | USD 0.0001 0.00 0.00% |
Nanobac Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Nanobac Pharmaceuticals from analyzing the firm fundamentals such as Return On Asset of -0.37, price to sales of 7.08 X, and Current Valuation of 124.75 K as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Nanobac Pharmaceuticals' valuation include:
Enterprise Value 124.8 K | Enterprise Value Ebitda (0.03) | Price Sales 7.0797 | Enterprise Value Revenue 7.0798 |
Overvalued
Today
Please note that Nanobac Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Nanobac Pharmaceuticals is based on 3 months time horizon. Increasing Nanobac Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Nanobac Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 0.0001, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of Nanobac Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nanobac Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nanobac Pharmaceuticals Incorporated helps investors to forecast how Nanobac stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nanobac Pharmaceuticals more accurately as focusing exclusively on Nanobac Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Nanobac Pharmaceuticals' intrinsic value based on its ongoing forecasts of Nanobac Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Nanobac Pharmaceuticals' closest peers.
Nanobac Pharmaceuticals Cash |
|
Nanobac Valuation Trend
Nanobac Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Nanobac Pharmaceuticals' financial worth over time. Using both Nanobac Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Nanobac Pharmaceuticals Total Value Analysis
Nanobac Pharmaceuticals Incorporated is now forecasted to have valuation of 124.75 K with market capitalization of 124.75 K, debt of 4.12 M, and cash on hands of 3.93 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nanobac Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
124.75 K | 124.75 K | 4.12 M | 3.93 K |
Nanobac Pharmaceuticals Investor Information
The company had not issued any dividends in recent years. Nanobac Pharmaceuticals had 1:4 split on the 27th of March 2000. Based on the key indicators related to Nanobac Pharmaceuticals' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Nanobac Pharmaceuticals Incorporated may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 264 | 251 |
|
|
Nanobac Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nanobac Pharmaceuticals has an asset utilization ratio of 0.24 percent. This connotes that the Company is making $0.002441 for each dollar of assets. An increasing asset utilization means that Nanobac Pharmaceuticals Incorporated is more efficient with each dollar of assets it utilizes for everyday operations.Nanobac Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 17.62 K. Net Loss for the year was (6.58 M) with profit before overhead, payroll, taxes, and interest of 3.1 K.About Nanobac Pharmaceuticals Valuation
The stock valuation mechanism determines Nanobac Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Nanobac Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nanobac Pharmaceuticals. We calculate exposure to Nanobac Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nanobac Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.6 K | 3.4 K | |
| Pretax Profit Margin | (429.18) | (407.72) | |
| Operating Profit Margin | 251.03 | 263.58 | |
| Net Loss | (429.18) | (407.72) | |
| Gross Profit Margin | 0.16 | 0.15 |
Nanobac Pharmaceuticals Current Valuation Indicators
Nanobac Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Nanobac Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Nanobac Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Nanobac Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Nanobac Pharmaceuticals' worth.Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.